Faecal Calprotectin and 7-α Cholestenone Levels in Microscopic Colitis: Experience from Edinburgh

Matt Davie1, Rebecca Trimble1, Alexander R Robertson2

  • 1The University of Edinburgh, NHS Lothian, Edinburgh EH16 4SA, UK.

Abstract

Insights

Elevated fecal calprotectin (FCP) may aid in diagnosing microscopic colitis (MC). 7 alpha-hydroxy-4-cholesten-3-one (7αC) showed low concordance with bile acid malabsorption (BAM) in MC patients.

Area of Science:

  • Gastroenterology
  • Clinical Diagnostics
  • Biomarker Research

Background:

  • Microscopic colitis (MC) presents as chronic watery diarrhea, lacking specific diagnostic biomarkers.
  • Fecal calprotectin (FCP) and bile acid malabsorption (BAM) are potential indicators in MC diagnosis and management.
  • 7 alpha-hydroxy-4-cholesten-3-one (7αC) is an alternative to SeHCAT for detecting BAM.

Purpose of the Study:

  • To evaluate fecal calprotectin (FCP) as a diagnostic biomarker for microscopic colitis (MC).
  • To assess the utility of 7 alpha-hydroxy-4-cholesten-3-one (7αC) in identifying bile acid malabsorption (BAM) in MC patients.

Main Methods:

  • Retrospective review of pathology records for collagenous colitis (CC) and lymphocytic colitis (LC) cases.
  • Extraction and analysis of FCP and 7αC results within six months of diagnosis.
  • Comparison of biomarker levels with established diagnostic criteria.

Main Results:

  • Elevated FCP was observed in 75.5% of CC patients and 57.1% of LC patients.
  • Bile acid malabsorption (BAM) was indicated by 7αC in 11.4% of CC and 25% of LC patients.
  • Mean 7αC levels suggested low concordance of BAM with MC in the studied cohort.

Conclusions:

  • Raised FCP levels support its potential role in the clinical diagnosis of microscopic colitis (MC).
  • 7αC can be used to identify BAM in MC patients, though concordance may be low.
  • Further research is warranted to establish FCP and 7αC in MC diagnostics.